The development of new parenteral biologics with high-volume, high-viscosity formulations is triggering the need for devices that can deliver these therapies with the ease, safety, and low injection time required for self-injection. Discover how companies can de-risk their device selection as they bring this new generation of biologics to market.
For individuals with chronic illnesses, managing medication can be a constant burden. New wearable injector technology is emerging to address this challenge. Explore the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.
This successful early feasibility clinical study of the BD Libertas™ Wearable Injector demonstrated consistent functional performance as designed with broad subject acceptability across all demographic categories and injection sites. Review how these results hold great promise for the future of subcutaneous chronic disease therapies.
BD Libertas™ Wearable Injector is designed to deliver subcutaneous injections of large volume (2-5 mL or 5-10 mL) and/or high viscosity (up to 50 cP) fixed dose biologics for the non-acute setting. Explore the improved patient experience offered by this advanced delivery system.
